Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

Expanded protocols promote early detection in high-risk patients and prevent hospital outbreaks of Candida auris.

Antipsychotics are the best defense against relapse in schizophrenia ... clozapine for people who the guidelines say have to ...